Atossa Therapeutics Inc (ATOS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.12-9.01%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ATOS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ATOS — dividend update
Dated 2026-10-09
Entry into a Material Definitive Agreement. On October 8, 2026, the Board of Directors (the “Board”) of Atossa Therapeutics, Inc. (the “Company”) declared a dividend of one stapled contingent value right (a “Stapled CVR”) for each share of the Company’s common stock, par value $0.18 per share (the “Common Stock”), outstanding at the close of business on October 19, 2026 (the “Record Date”), and authorized the issuance of one Stapled CVR with respect to each share of Common Stock that becomes…
Why it matters: The trial has finished enrollment. Its results can show whether (Z)-endoxifen has activity in breast cancer.
Watch forThe 4Q26 data show the trial met its stated clinical goals and had a measurable benefit.
Also watch forThe data miss the stated clinical endpoints, show no benefit, or are delayed past 4Q26.
Why it matters: These data can test the planned path toward a larger MAS study. A clear delay or weak result would slow that path.
Watch forAtossa reports final Phase 2 data by June 30, 2027, with results that support moving to the planned next study.
Also watch forThe final data miss their stated endpoints, fail to support the next study, or arrive after June 30, 2027.
Why it matters: Atossa reported $26.1 million in cash at June 30 and has no approved product. New funding or faster cash use could shape trial plans.
Watch forThe November 11 report shows cash above $26.1 million, or confirms access to the stated warrant proceeds. No new funding is needed.
Also watch forCash falls below $26.1 million and Atossa reports new share sales, a funding need, or reduced study plans.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$290 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $798 loss on $10,000 · 8.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,711 loss on $10,000 · 87.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.